{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(4)"],"submitter":["Dobersberger M"],"funding":["Austrian Science Fund FWF","Christian Doppler Research Association"],"pubmed_abstract":["Chimeric antigen receptor (CAR) T cells have shown remarkable response rates in hematological malignancies. In contrast, CAR T cell treatment of solid tumors is associated with several challenges, in particular the expression of most tumor-associated antigens at lower levels in vital organs, resulting in on-target/off-tumor toxicities. Thus, innovative approaches to improve the tumor specificity of CAR T cells are urgently needed. Based on the observation that many human solid tumors activate epidermal growth factor receptor (EGFR) on their surface through secretion of EGFR ligands, we developed an engineering strategy for CAR-binding domains specifically directed against the ligand-activated conformation of EGFR. We show, in several experimental systems, that the generated binding domains"],"journal":["Cell reports methods"],"pagination":["100728"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11045874"],"repository":["biostudies-literature"],"pubmed_title":["An engineering strategy to target activated EGFR with CAR T cells."],"pmcid":["PMC11045874"],"pubmed_authors":["Seigner J","Emminger D","Zajc CU","Bobbili MR","Sylvander E","Dobersberger M","Teufl M","Lehner E","Traxlmayr MW","Sumesgutner D","Laurent E","Salzer B","Lehner M","Kunert R"],"additional_accession":[]},"is_claimable":false,"name":"An engineering strategy to target activated EGFR with CAR T cells.","description":"Chimeric antigen receptor (CAR) T cells have shown remarkable response rates in hematological malignancies. In contrast, CAR T cell treatment of solid tumors is associated with several challenges, in particular the expression of most tumor-associated antigens at lower levels in vital organs, resulting in on-target/off-tumor toxicities. Thus, innovative approaches to improve the tumor specificity of CAR T cells are urgently needed. Based on the observation that many human solid tumors activate epidermal growth factor receptor (EGFR) on their surface through secretion of EGFR ligands, we developed an engineering strategy for CAR-binding domains specifically directed against the ligand-activated conformation of EGFR. We show, in several experimental systems, that the generated binding domains","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-03T03:57:47.199Z","creation":"2026-04-24T03:09:42.333Z"},"accession":"S-EPMC11045874","cross_references":{"pubmed":["38492569"],"doi":["10.1016/j.crmeth.2024.100728"]}}